SparingVision raises €75m for eye disease gene therapies

SparingVision has raised €75 million in second-round funding that will be used to fund clinical trials of gene therapies for ocular diseases retinitis pigmentosa (RP) and dry age-related ma

First UK patients get Novartis’ Luxturna gene therapy for bl...

Finding the right reimbursement model for gene therapies

With cell and gene therapies growing more and more important to healthcare, we sat down with Debbie Warner, vice president of Kantar’s Health division, to learn how the industry can overcome fu

Roche insists Spark deal is still on, despite lacklustre tak...

Shareholders in Spark Therapeutics haven’t been queueing up to take advantage of Roche’s $114.50-per-share offer, forcing an extension to the tender process.

Novartis snaps up ex-US partnership with Spark on gene thera...

I was at Novartis headquarters in Basel yesterday for the company’s Q4 results, and my burning question was – did the company have any designs on entering the viral vector-based gene therap